Recent studies tried to assess the behavior of hybrid peptides such as GLP1 linked with glucagon, GIP or any other intestinal peptide, in an effort to lower blood glucose levels in T2DM patients [73]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.